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Prevention of Sudden
Death for Patients
With Cardiomyopathies
Another Step Forward*
Barry J. Maron, MD,†
Christopher Semsarian, MBBS, PHD‡
Minneapolis, Minnesota; and Sydney, Australia
It has now been 30 years since the implantable cardioverter-
efibrillator (ICD) was introduced to the cardiovascular
ommunity for the prevention of sudden cardiac death
1). Perhaps it is no longer common knowledge that the
efibrillator was conceived and initially developed 40
ears ago by Drs. Michel Mirowski and Morton Mower,
ot in an eminent medical institution with the robust
upport of industry and the National Institutes of Health,
ut rather in the basement of a small, private hospital (Sinai
ospital, Baltimore, Maryland), initially with no formal
unding. This entirely novel concept was initially met with
ubstantial skepticism and even antagonism (2), but even-
ually moved forward, driven by the vision of Mirowski and
ower, until it became the acknowledged treatment to
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prevent sudden death due to ventricular tachyarrhythmias,
largely for high-risk patients with coronary artery disease
(CAD) and myocardial infarction. Certainly, it was not
unexpected that this large group of patients would become
the impetus for developing the ICD, as well as the core
recipients of this technology, as it evolved over the decades
with numerous randomized trials documenting its efficacy
and superiority over pharmacologic strategies (3–5).
However, it is not generally appreciated that most of a
small group of exceptionally high-risk patients selected for
initial clinical testing of the ICD in the laboratory setting
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ventricular fibrillation) did not have ischemic heart disease
but, rather, a much less common genetic heart disease,
hypertrophic cardiomyopathy (HCM). During the ensuing
2 decades of ICD development, while there were important
advances such as transvenous lead systems, which permitted
these devices to be employed more widely for primary
prevention, nevertheless, genetic cardiomyopathies were
largely ignored.
Not until 2000 was the ICD introduced to HCM
patients with nonatherosclerotic genetic heart disease as a
systematic, effective strategy for sudden death prevention in
an international, multicenter registry study (6). This trans-
lation of the ICD to HCM was logical and necessary, given
that HCM is the most common cause of sudden death in
young people (7) who have many years of potentially
productive life ahead. Indeed, over the last decade, the ICD
has proven life-saving for many HCM patients, with pri-
mary prevention appropriate intervention rates of 4% per
year (10% per year for secondary prevention). After the
initial experience with HCM, the ICD has proved effective
in patients with other genetic heart diseases such as arrhyth-
mogenic right ventricular cardiomyopathy/dysplasia, an en-
tity very different morphologically, but with similar reported
ICD intervention rates (10–12).
Notably, in this issue of the Journal, van Rijsingen et al.
(13) expand the role of the ICD for prevention of sudden
death by reporting outcomes of an observational study from
8 centers in 6 European countries (Netherlands, Italy,
Denmark, United Kingdom, France, and Germany). The
study population includes 269 patients and relatives (from
109 families) with pathogenic lamin A/C (LMNA) gene
mutations responsible for dilated cardiomyopathy and sys-
tolic dysfunction (some with muscular dystrophy). Approx-
imately 20% of the patients had demonstrated malignant
ventricular tachyarrhythmias manifest by either resuscitated
cardiac arrest, sudden cardiac death, or (for approximately
half) appropriate interventions from primary prevention
ICDs. Indeed, of 107 patients implanted prophylactically
with an ICD, 25 (or 23%) experienced an intervention for
ventricular tachycardia/fibrillation over a 29-month follow-
up, for a particularly substantial intervention rate of about
9% per year. Unfortunately, while there is abundant demo-
graphic data provided for the overall study group of 269
patients, some information of interest for this specific ICD
subset appears to be lacking, such as the age at implant or
time from implant to ICD shock, and the level of limiting
symptoms experienced prior to device intervention.
It is now apparent that the ICD will intervene reliably in
genetic cardiomyopathies such as HCM, arrhythmogenic
right ventricular cardiomyopathy/dysplasia, and now
LMNA-mediated dilated cardiomyopathy to terminate life-
threatening ventricular arrhythmias and abort catastrophe.
However, the key remaining clinical issue (and often di-
lemma) is the proper selection of patients who will benefit
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gen et al. (13) have used a noninvasive risk stratification
algorithm including a variety of clinical variables to select
patients for prophylactic ICDs similar in principle to that
previously promoted in HCM (7–9). The authors’ novel
multivariate model identified 4 variables as independent risk
factors: nonsustained ventricular tachycardia (on 24-h am-
bulatory [Holter] electrocardiogram), ejection fraction
45%, male gender, and non-missense mutations.
However, the most notable differences from HCM in this
regard are the exclusion of family history of sudden death as
a predictor, and the inclusion of a predictive genotype,
namely, non-missense mutations such as insertions/
deletions, truncating or mutations affecting splicing, which
can lead to significant alterations in the encoded protein. In
contrast, while the majority of disease-causing mutations in
HCM are missense (single amino acid substitutions), there
is little evidence that either missense or non-missense
mutations predict clinical course and prognosis in that
disease.
Two or more of the risk markers in LMNA mutation
carriers predicted malignant ventricular tachyarrhythmias
and permitted effective primary prevention of sudden death
through reliable selection of patients for ICDs. The 2 risk
factor model has been favored by European investigators in
defining high risk status in genetic cardiomyopathies (e.g.,
HCM), whereas others have promoted the principle that 1
major risk factor in the clinical profile of an individual
patient can be sufficient to consider the option of a primary
prevention ICD. Therefore, it would be of interest to learn
whether 1 risk factor was predictive in at least some of the
authors’ LMNA patients, i.e., are the 4 risk markers of equal
eight in a given LMNA mutation carrier? Is a reduced
ejection fraction alone sufficient to justify an ICD? These
are among the many questions remaining in this early
experience with sudden death prevention for patients with
genetic dilated cardiomyopathy that will require studies in
larger patient cohorts. It is also of interest that a family
history of sudden death did not prove to be a risk factor in
the LMNA mutation carriers (13), consistent with the
experience in long-QT syndrome (14) and Brugada syn-
drome (15), but in contrast to HCM (16).
This is a complex paper to read, with much data, but the
readership should not be dissuaded from an appreciation of
its most important message—namely, that by virtue of a
clinical-genetic risk stratification model, those LMNA mu-
tation carriers most likely to benefit from ICD therapy have
been identified, thereby saving many lives with another
inherited heart disease. Indeed, the multicenter report of
van Rijsingen et al. (13) makes a major contribution to themanagement of such patients, and in a historical context,
one that was certainly unforeseen 4 decades earlier by the
visionary investigators who created the ICD.
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